Immune Response Corp., maker of the experimental HIV vaccine Remune, last week announced the appointment of John Bonfiglio as the company's new chief executive officer. He will be charged with spearheading the company's development of Remune, currently in clinical trials for possible use in combination with antiretroviral drugs to slow or stop HIV replication in people infected with the virus. "A significant factor in any HIV treatment development is the importance of the HIV activist and medical communities, whose long-term advocacy and input have been instrumental in the advancement of new treatments," Bonfiglio said. "I look forward to working closely with these groups as we pursue the ongoing development of Remune."
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














